Forge Biologics Cleared for Clinical Trial of FBX-101, a Krabbe Disease Treatment
The FDA has recently cleared an Investigational New Drug (IND) application for FBX-101, allowing it to move into a Phase 1/2 clinical trial. This gene therapy was developed for the…